Novozymes

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Novozymes A/S
Type Publicly traded Aktieselskab
Traded as OMXNZYM B
Industry Biotechnology
Founded 2000
Headquarters Bagsværd, Denmark
Key people Henrik Gürtler (Chairman), Peder Holk Nielsen (President and CEO)
Products Enzymes, microorganisms
Revenue DKK 10.510 billion (2011)[1]
Operating income DKK 2.340 billion (2011)[1]
Profit DKK 1.828 billion (2011)[1]
Employees 6,041 (2012)[2]
Website www.novozymes.com

Novozymes is a biotech-based company, headquartered in Denmark and employing approximately 6,000 people in 30 countries. Novozymes A/S’ B shares are listed on the NASDAQ OMX Nordic.

History[edit]

In 1925 the brothers Harald and Thorvald Pedersen founded Novo Terapeutisk Laboratorium with the aim to produce insulin. In the mid 1930s Novozymes built the first office in Copenhagen. In 1941 Novozymes launched its first enzyme, trypsin, extracted from the pancreas of animals and used to soften leather.

The company was the first to produce enzymes by fermentation using bacteria in 1952. In the late 1980s Novozymes presented the world’s first fat-splitting enzyme for detergents manufactured with genetically engineered microorganisms. In the 2000s Novozymes expanded through acquisition of several companies focusing on business outside the core enzyme business. Amongst them were the Brazilian bioagricultural company Turfal and German pharmaceutical, chemical and life science company EMD/Merck Crop BioScience Inc. These acquisitions made Novozymes the largest player in sustainable solutions for the agricultural biological industry.

Business areas and technologies[edit]

Novozymes' business is divided into three areas: Enzymes for industrial use, microorganisms, and biopharmaceutical ingredients accounting for respectively 90%, 7% and 3% of sale, respectively (2011).[3] Novozymes markets approximately 700 different products worldwide.

Ownership[edit]

The Novozymes A share capital is held by Novo A/S, a wholly owned subsidiary of the Novo Nordisk Foundation. In addition, Novo A/S holds 5,826,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 70.1% of the votes.

Novozymes A/S' B shares are listed on the NASDAQ OMX Nordic and are traded under the abbreviated name NZYM B and the ID code/ISIN DK0010272129. The B shares are issued in units of DKK 10.

Each A share carries the right to cast one hundred votes at the company's shareholders' meeting, each B share the right to cast ten votes.

References and footnotes[edit]

  1. ^ a b c "Annual Report 2011". Novozymes. Retrieved 21 January 2011. 
  2. ^ "Annual Report 2012". Novozymes. Retrieved 2 February 2012. 
  3. ^ The Novozymes Report 2010

External links[edit]